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Utilizing Ethnic-Specific Differences
in Minor Allele Frequency to Recategorize
Reported Pathogenic Deafness Variants
A. Eliot Shearer,1 Robert W. Eppsteiner,1,18 Kevin T. Booth,1,18 Sean S. Ephraim,2,18 Jose´ Gurrola, II,1
Allen Simpson,1 E. Ann Black-Ziegelbein,1 Swati Joshi,3 Harini Ravi,3 Angelica C. Giuffre,3 Scott Happe,3
Michael S. Hildebrand,4 Hela Azaiez,1 Yildirim A. Bayazit,5 Mehmet Emin Erdal,6
Jose A. Lopez-Escamez,7 Irene Gazquez,7 Marta L. Tamayo,8 Nancy Y. Gelvez,8 Greizy Lopez Leal,8
Chaim Jalas,9 Josef Ekstein,10 Tao Yang,11 Shin-ichi Usami,12 Kimia Kahrizi,13 Niloofar Bazazzadegan,13
Hossein Najmabadi,13 Todd E. Scheetz,2,14,15 Terry A. Braun,2,14,15 Thomas L. Casavant,2,14,15
Emily M. LeProust,3,19 and Richard J.H. Smith1,16,17,*
Ethnic-specific differences in minor allele frequency impact variant categorization for genetic screening of nonsyndromic hearing loss
(NSHL) and other genetic disorders. We sought to evaluate all previously reported pathogenic NSHL variants in the context of a large
number of controls from ethnically distinct populations sequenced with orthogonal massively parallel sequencing methods. We used
HGMD, ClinVar, and dbSNP to generate a comprehensive list of reported pathogenic NSHL variants and re-evaluated these variants
in the context of 8,595 individuals from 12 populations and 6 ethnically distinct major human evolutionary phylogenetic groups
from three sources (Exome Variant Server, 1000 Genomes project, and a control set of individuals created for this study, the OtoDB).
Of the 2,197 reported pathogenic deafness variants, 325 (14.8%) were present in at least one of the 8,595 controls, indicating a minor
allele frequency (MAF)>0.00006. MAFs ranged as high as 0.72, a level incompatible with pathogenicity for a fully penetrant disease like
NSHL. Based on these data, we establishedMAF thresholds of 0.005 for autosomal-recessive variants (excluding specific variants inGJB2)
and 0.0005 for autosomal-dominant variants. Using these thresholds, we recategorized 93 (4.2%) of reported pathogenic variants as
benign. Our data show that evaluation of reported pathogenic deafness variants using variant MAFs from multiple distinct ethnicities
and sequenced by orthogonal methods provides a powerful filter for determining pathogenicity. The proposedMAF thresholds will facil-
itate clinical interpretation of variants identified in genetic testing for NSHL. All data are publicly available to facilitate interpretation of
genetic variants causing deafness.The advent of massively parallel sequencing has shifted
the bottleneck in human genetics from data acquisition
to variant interpretation. Accurate evaluation of genetic
variants for pathogenicity is crucial to advance our under-
standing of disease processes and is a requirement for
clinical diagnostics. Whole-exome sequencing and tar-
geted gene panels based on targeted genomic enrichment
and massively parallel sequencing are becoming common-
place and for some Mendelian diseases, including breast
and ovarian cancer, degenerative eye disease, and hearing
loss, they have become the ideal test and are now used
routinely for clinical diagnostic testing.1–3 These tests regu-
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The Americrequire categorization and interpretation to assess their
likelihood of causing disease. Correct interpretation is
crucial when test results are used to direct clinical care.
Hearing loss (HL) is the most common sensory deficit in
humans, affecting 1 in 500 children4 and 360 million peo-
ple worldwide (World Health Organization Deafness Esti-
mate Online Report). The majority of HL is genetic and
nonsyndromic (NSHL, not associated with other clinical
phenotypes). Genetic diagnosis for NSHL is particularly
challenging given limited phenotypic variability and
extreme genetic heterogeneity; increased use of massively
parallel sequencing resulting in thousands of variants
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Figure 1. Study OverviewTo date more than 70 genes and more than 2,000 causal
variants have been implicated in NSHL. As with other
genetic diseases, the vast majority of reported pathogenic
NSHL variants were so designated based on five primary
criteria: (1) cosegregation with the phenotype ideally
with linkage analysis, (2) absence in 200 or more control
chromosomes from the same ethnicity, (3) conservation
of the affected nucleotide or amino acid through evolu-
tion, (4) predicted functional effect of the mutation, and
(5) corroborative in vitro or in vivo functional data.
Absent, however, has been a sixth criterion—one that
would require assessment of the variant in the context of
a large number (thousands) of controls from varying eth-
nicities. This omission is noteworthy because the majority
of human genetic variation is accounted for by ethnicity-
specific differences.5,6 Our group and others have hypoth-
esized that evaluation of variants in this context can
reduce or eliminate false positives. Massively parallel
sequencing techniques have for the first time delivered446 The American Journal of Human Genetics 95, 445–453, Octoberthe ability to sequence a heretofore-unobtainable number
of control individuals from different ethnicities with data
freely available to the scientific community.
In the first application of a large amount of control data
to evaluate a human genetic disease, Norton et al. pro-
posed a disease-specific iterative approach: use a large
number of controls to determine the minor allele fre-
quency (MAF) of known pathogenic variants and thereby
determine a MAF cut-off that can be used for evaluation
of future variants.7 The authors used data from the Exome
Variant Server (EVS), which includes two ethnically
distinct populations, to resolve false positives. Another
recent study disqualified ten reported X-linked disability
genes using similar methods and data from the EVS.8
Most recently, a gene with variants reported to cause
NSHL, MYO1A (MIM 601478), has been disqualified
through the use of EVS and lack of cosegregation of previ-
ously reported pathogenic variants in this gene.9
Incorrect classification of genetic variants as pathogenic
is not limited to only one or a few genetic diseases—it is a
systemic issue in human genetics. Cassa et al. evaluated all
of the mutations present in the Human Gene Mutation
Database (HGMD), the most comprehensive repository of
pathogenic human mutations, in the context of control
data from the 1000 Genomes Project.10 The authors found
that 3.5% of variants present in HGMDhave aMAF> 0.05,
which is implausible for a highly penetrant Mendelian
disease.
Our goal in this study was to evaluate all reported path-
ogenic deafness variants in the context of a large number
of controls from multiple ethnicities in order to recatego-
rize any clearly benign variants based on MAF in controls
and establish MAF thresholds to aid interpretation of vari-
ants discovered in the future (Figure 1).
We sought to evaluate pathogenic variants present in
66 genes with variants reported to cause NSHL and
NSHL-mimic syndromes (genetic causes of syndromic
hearing loss that mimic NSHL at presentation such as
Usher syndrome, the most common cause of deaf-blind-
ness; see Table S1 [available online] for a complete gene
list). Reported pathogenic deafness variants were obtained
from three sources: HGMD (Professional v.2013.4), NCBI
ClinVar, and dbSNP v.138 (the latter publically available
databases were accessed in February 2014). When neces-
sary, variants were converted to HGVS nomenclature using
Mutalyzer to generate genomic coordinates.11 The final
comprehensive list of reported pathogenic deafness vari-
ants included all variants categorized as fully penetrant
pathogenic or probable-pathogenic in any of the databases
(DM or DM? in the case of HGMD).
In total, we obtained 2,197 variants designated as path-
ogenic or probable-pathogenic by any of three databases.
As shown in Figure S1, the majority of these variants
were identified in HGMD alone (1,572; 71.6%), seven
were unique to ClinVar, and none were unique to dbSNP.
The three databases shared 454 (20.7%) of the reported
pathogenic variants.2, 2014
Table 1. Previously Reported Pathogenic Deafness-Causing
Variants
Variant Type All
Autosomal
Recessive
Autosomal
Dominant X-Linked
Nonsynonymous 1,165 972 173 20
Stop gain 350 336 7 7
Stop loss 3 2 1 –
Synonymous 31 28 3 –
Splice site 238 232 6 –
Frameshift deletion 330 311 9 10
Frameshift insertion 25 24 – 1
Nonframeshift deletion 46 35 9 2
Nonframeshift insertion 9 9 – –
Total 2,197 1,949 208 40There was disagreement between databases in the cate-
gorization of 96 variants. All differences were between
HGMD and the other two databases, ClinVar and dbSNP,
which agreed in all cases. HGMD categorized 87 variants
pathogenic while the other two databases categorized the
same variants as probable-pathogenic (41), probable-
nonpathogenic (20), or nonpathogenic (26). HGMD cate-
gorized 9 variants as probable-pathogenic while the other
two databases categorized these variants as pathogenic.
Of the 2,197 reported pathogenic deafness variants,
1,165 were nonsynonymous, 350 were stop gain, 330
were frameshift deletions, 238 were splice site mutations,
46 were non-frameshift deletions, 31 were synonymous,
25 were frameshift insertions, 9 were nonframeshift inser-
tions, and 3 were stop loss (Table 1). When divided by the
mode of inheritance, there were 1,949 autosomal-reces-
sive, 208 autosomal-dominant, and 40 X-linked recessive
pathogenic variants.
In total, we ascertained 8,595 control individuals
from 12 populations and 6 major phylogenetic groups of
human evolutionary history using three orthogonal
massively parallel sequencing methods. The populations
ranged in size from 100 to 4,300 individuals (Table 2). Con-
trol data were obtained from three sources: (1) the NHLBI
Go Exome Sequencing Project (ESP), made available on
the Exome Variant Server (EVS) version ESP6500SI-V2 ac-
cessed 2/2014, (2) the 1000 Genomes Project (1000G)
release 1000GApr2012, and (3) the OtoDB, the OtoSCOPE
Control Database, data from 1,000 normal hearing con-
trols from six populations, which we generated for this
project by pooled targeted genomic enrichment (methods
described in detail below). A summary of the controls used
in this study is provided in Table 2.
The EVS database includes 6,503 individuals from two
populations—4,300 European Americans (EA) and 2,203
African Americans (AA)—and was established to study in-
dividuals on the extremes of cardiovascular phenotypes
as well as control individuals. Whole-exome sequencingThe Americ(WES) was performed on these samples with a target
average coverage >803. Coverage statistics for the genes
targeted in this study were calculated using BED files pro-
vided by the ESP.
The 1000G database includes 1,092 individuals from
4 superpopulations (large populations comprised of several
subpopulations, generally from the same geographic region
and shown to be closely related in evolutionary history):
246 samples from the African superpopulation (AFR), 181
samples from the American superpopulation (AMR), 286 in-
dividuals from the Asian superpopulation (ASN), and 379
individuals from the European superpopulation (EUR).
Variant calls were obtained from a combination of WES
and low-coverage whole-genome sequencing (WGSþWES).
Coverage statistics for genes targeted in this study were
calculated from BAM files for ten individuals.
The OtoDB includes 1,000 normal-hearing individuals
from six populations sequenced using pooled targeted
genomic enrichment and massively parallel sequencing
(PTEþMPS). The populations included (1) 200 Ashkenazi
Jews living in New York (AJ), (2) 160 Colombians origi-
nating from different cities around the country including
Bogota´ and the central region, the Atlantic coast, and the
north, west, and southwest regions of the country (CO),
(3) 200 Japanese students attending Shinshu University
in Matsumoto (JP), (4) 160 European Americans from
Iowa, USA (US), (5) 180 Spanish fromAlmerı´a and Granada
(ES), and (6) 100 Turks, primarily from the Southern and
Mediterranean Sea regions (TR). All samples were from in-
dividuals with no self-reported hearing loss, and in the case
of Japanese samples, subjects had audiometric testing
showing no evidence of hearing loss. Individuals from
the EVS and 1000G databases, in contrast, were not evalu-
ated for hearing loss and therefore are not true ‘‘controls’’
but rather representative cross-sections of their derivative
populations. Human ethics and institutional review board
(IRB) policies were followed at each institution where
samples were collected and informed consent was ob-
tained. All methods were approved by the IRB at the
University of Iowa.
To sequence the 1,000 OtoDB controls, we used a pooled
targeted genomic enrichment method that entailed gener-
ating 50 pools, each of which included 20 DNA samples
(40 alleles per pool). We then performed targeted genomic
enrichment andmassively parallel sequencing as described
using automation equipment.3 We captured the exonic re-
gions of 66 genes with variants causing NSHL, targeting in
total 1,344 regions and 521,647 bp of the genome (Table
S1). Molecular barcodes were added to each pool of 20
DNA samples. Five pools were then multiplexed and
sequenced in a single flow-cell of the Illumina HiSeq using
100 bp paired-end reads (100 samples per flow-cell). We
sought to generate a sequencing depth-of-coverage suffi-
cient for variant calling for each allele present in the pool
for all targeted regions (103 per sample or 2003 per pool).
We analyzed the pooled data sets using a local installation
of the open-source Galaxy software12 and the followingan Journal of Human Genetics 95, 445–453, October 2, 2014 447
Table 2. Populations Used in This Study
Phylogenetic
Group Population n Individuals
DB
Source DB Type
African AFR: African
superpopulation
246 1000G WGSþWES
AA: African
American
2,303 EVS WES
American AMR: American
superpopulation
181 1000G WGSþWES
CO: Colombia 160 OtoDB PTEþMPS
East Asian ASN: Asian
superpopulation
286 1000G WGSþWES
JP: Japan 200 OtoDB PTEþMPS
European EUR: European
superpopulation
379 1000G WGSþWES
EA: European
American
4,300 EVS WES
US: Europeans
from USA
160 OtoDB PTEþMPS
ES: Spain 180 OtoDB PTEþMPS
European,
isolated
AJ: Ashkenazi
Jewish
200 OtoDB PTEþMPS
Mediterranean TR: Turkey 100 OtoDB PTEþMPS
Total 8,595
Abbreviations are as follows: 1000G, 1000 Genomes Project; EVS, Exome
Variant Server; OtoDB, OtoSCOPE Control Database; WGS, whole-genome
sequencing; WES, whole-exome sequencing; PTE, pooled targeted enrich-
ment; MPS, massively parallel sequencing.steps: read mapping with Burrows-Wheeler Alignment
(BWA),13 duplicate removal with Picard, local realign-
ment with GATK,14 and variant calling with SAMtools.15
Coverage statistics were calculated with BEDTools.16 Vari-
ant frequency in each pool was assigned using vipR, a pre-
viously validated method that accurately calls variants
in pooled data sets using skellam distributions.17 We ran
vipR using default parameters except we enabled indel call-
ing. Annotation of identified variants was performed with
ANNOVAR.18
For the pooled OtoDB control set, the average pool
depth of coverage was 7,846 for an average inferred per-
sample depth of coverage of 3923. To validate pooled
sequencing and the vipR analysis method, we used Sanger
sequencing and genotyped 12 single-nucleotide changes
in 100 persons comprising 5 pools including 7 variants
showing the minimum frequency in the pool (1 allele in
40, frequency of 0.025). We found a sensitivity of 0.971
and specificity of 0.989 when using Sanger sequencing as
the gold standard (Table S2).
As expected, coverage statistics for the 66 targeted NSHL
genes varied by data source due to the different sequencing
methods used (Table S3). Because coding variants comprise
the majority of pathogenic mutations, we focused on
exons and found thatR13 exonic coverage of these genes
was 68.9%, 82.6%, and 99.8% with EVS, 1000 Genomes,448 The American Journal of Human Genetics 95, 445–453, Octoberand OtoDB, respectively. When restricted to coding exons
only, R13 coverage was 88.7%, 93.8%, and 99.4% (Table
S3). Average overall coding depth of coverage was 246,
90, and 475 for EVS, 1000 Genomes, and OtoDB, respec-
tively. These data provided the source for annotation of
the identified pathogenic variants.
Of the 2,197 pathogenic variants obtained from the
three databases, we found 325 variants (14.8%) in controls.
Fifty-seven of these variants (17.5%) were present in all
three databases (Figure S2). By inheritance pattern, 296
and 29 pathogenic variants were associated with auto-
somal-recessive and autosomal-dominant NSHL, respec-
tively. There were no reported X-linked NSHL variants in
controls. In aggregate, of the 42 autosomal-recessive and
20 autosomal-dominant NSHL genes we screened, 24
recessive and 9 dominant genes contained pathogenic var-
iants in controls (Table 3).
As shown in Table 3, the proportion of pathogenic vari-
ants in controls varied by gene and was highest at 86% for
MYO1A. Variants in this gene were recently discounted as
causing autosomal-dominant NSHL.9 Other genes with a
high proportion of pathogenic variants found in controls
include 50% for DFNB31 (MIM 607084), GJB3 (MIM
603324), GRXCR1 (MIM 613283), SLC26A5 (MIM
604943), and DIAPH1 (MIM 602121). The minor allele fre-
quencies (MAF) for these variants ranged from the limit of
detection, which was 0.00006, to 0.72 for GJB2 (MIM
121011; RefSeq accession number NM_004004; c.79G>A
[p.Val27Ile]) in the Japanese population of OtoDB, a
variant that is commonly considered nonpathogenic but
is labeled as probable-nonpathogenic by ClinVar and
dbSNP and probable-pathogenic by HGMD. We noted
that several variants had MAF levels implausible for a fully
penetrant Mendelian disease like deafness.
The remaining 1,872 variants (85.2%) were not identi-
fied in the 8,595 controls consistent with extreme rarity
(<1/17,190 alleles or a MAF < 0.00006) and indicating
an increased likelihood of pathogenicity. The distribution
of pathogenic variants by MAF is shown in Figure 2. We
evaluated variants using the maximum MAF (Max MAF),
the highest MAF in any one of the 12 populations studied.
Detailed data for each variant including MAF per popula-
tion are provided online in full at the Deafness Variation
Database (see Web Resources section).
Based on these data, we sought to identify appropriate
MAF cut-offs for autosomal-recessive and autosomal-domi-
nant NSHL. For severe-to-profound autosomal-recessive
congenital NSHL, there are a wealth of data showing that
the most common genetic cause in most world popula-
tions are mutations in GJB2, with specific variants like
c.35delG and c.167delT having exceptionally high fre-
quencies in the European and Jewish populations, respec-
tively. The aggregate GJB2 mutation carrier frequency in
these populations is typically 1%–2%.
We used these data to create an empirically based cut-off
for autosomal-recessive NSHL by first positing a MAF of
0.01 for any autosomal-recessive NSHL-causing variant in2, 2014
Table 3. Previously Reported Pathogenic Deafness-Causing Variants Identified in All Individuals Studied by Gene
Gene
n Reported Path.
Variants
% of Path. Variants
Identified in Individuals (n) MAF Range
% of Path. Variants
Recategorized Benign (n)
Autosomal Recessive
CDH23 166 14% (24) 0.0001–0.1417 2% (4)
CLDN14 6 33% (2) 0.0001–0.0002 –
CLRN1 24 29% (7) 0.0001–0.0075 4% (1)
COL11A2 1 0 (0) – –
DFNB31 14 50% (7) 0.0001–0.01 7% (1)
DFNB59 13 8% (1) 0.0001–0.0003 –
ESPN 6 0 (0) – –
ESRRB 8 13% (1) 0.0002 –
GIPC3 9 0 (0) – –
GJB2 277 15% (42) 0.0001–0.7225 2% (6)
GJB3 6 50% (3) 0.0003–0.0307 33% (2)
GJB6 9 11% (1) 0.0003–0.0005 -
GPR98 51 18% (9) 0.0001–0.04 8% (4)
GPSM2 2 0 (0) – –
GRHL2 2 0 (0) – –
GRXCR1 4 50% (2) 0.0001–0.06 –
HGF 1 0 (0) – –
ILDR1 12 0 (0) – –
LHFPL5 5 0 (0) – –
LOXHD1 7 43% (3) 0.0007–0.06 14% (1)
LRTOMT 8 0 (0) – –
MARVELD2 6 0 (0) – –
MYO15A 52 17% (9) 0.0001–0.014 8% (4)
MYO3A 4 0 (0) – –
MYO6 2 0 (0) – –
MYO7A 257 11% (27) 0.0001–0.14 2% (6)
OTOA 2 0 (0) – –
OTOF 110 20% (22) 0.0001–0.03 5% (5)
PCDH15 41 15% (6) 0.0001–0.0945 10% (4)
RDX 3 0 (0) – –
SLC26A4 339 16% (53) 0.0001–0.1428 4% (12)
SLC26A5 2 50% (1) 0.002–0.0156 50% (1)
STRC 15 13% (2) 0.0002–0.0004 7% (1)
TECTA 10 0 (0) – –
TMC1 36 25% (9) 0.0001–0.0031 –
TMIE 10 0 (0) – –
TMPRSS3 27 33% (9) 0.0001–0.0483 7% (2)
TPRN 5 0 (0) – –
TRIOBP 9 11% (1) 0.0001 –
(Continued on next page)
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Table 3. Continued
Gene
n Reported Path.
Variants
% of Path. Variants
Identified in Individuals (n) MAF Range
% of Path. Variants
Recategorized Benign (n)
USH1C 24 29% (7) 0.0001–0.06 8% (2)
USH1G 9 0 (0) – –
USH2A 354 13% (47) 0.0001–0.1743 5% (17)
Autosomal Dominant
ACTG1 11 0 (0) – –
COCH 16 6% (1) 0.0001 –
COL11A2 2 0 (0) – –
CRYM 2 0 (0) – –
DFNA5 2 0 (0) – –
DIAPH1 2 50% (1) 0.0035 50% (1)
DSPP 2 0 (0) – –
GJB2 30 3% (1) 0.01 3% (1)
GJB3 9 44% (4) 0.0001–0.02 44% (4)
GJB6 3 33% (1) 0.0002–0.0006 33% (1)
KCNQ4 19 0 (0) – –
MYH14 6 17% (1) 0.0007–0.01 17% (1)
MYH9 1 0 (0) – –
MYO1A 7 86% (6) 0.0002–0.1125 57% (4)
MYO6 6 0 (0) – –
MYO7A 7 0 (0) – –
POU4F3 7 0 (0) – –
TECTA 39 18% (7) 0.0001–0.0031 10% (4)
TMC1 3 0 (0) – –
WFS1 34 21% (7) 0.0001–0.0232 12% (4)
Abbreviations are as follows: path., pathogenic; MAF, minor allele frequency.GJB2. Our data, for example, gave a maximum MAF of
0.0108 and 0.01 for GJB2 (RefSeq NM_004004): c.35delG
and c.167delT, respectively. Next, we assumed the exis-
tence of a single mutation in a second gene that accounts
for roughly one-quarter of all remaining recessive NSHL, a
very liberal assumption given the documented genetic het-
erogeneity. The MAF of this variant would be 0.005. We
then hand-curated the 83 recessive NSHL variants with
MAFs > 0.005 for plausibility of pathogenicity and recate-
gorized 73 variants as benign (Figure 2 and Table S4).
To evaluate the predicted effects of nonsynonymous
changes, we used six pathogenicity prediction algori-
thms derived from dbNSFP v.2.319 and annotated with
ANNOVAR: SIFT, Polyphen2_HVAR, LRT, MutationTaster,
MutationAssessor, and FATHMM. We used these methods
to evaluate variants individually and as part of a com-
posite pathogenicity score. For the composite score
(path_composite), a score of 1 point was assigned for
each tool indicating pathogenicity or likely pathogenicity.
Because pathogenicity predictions were not available for450 The American Journal of Human Genetics 95, 445–453, Octoberevery variant for each tool, the sum was divided by the
total number of predictions available for that variant to
create a ratio from 0 to 1. We also used the MetaLR score,
a radial support-vector machine (SVM) method trained
with a hand-curated list of causative variants and scored
using several available pathogenicity tools. MetaLR is
part of the ANNOVAR suite and initial studies have shown
that its performance is superior to other pathogenicity
prediction tools.
To test the plausibility of this MAF threshold for auto-
somal-recessive NSHL in an outbred population, we used
these methods to evaluate the recessive variants we recate-
gorized as benign and compared this score to the pathoge-
nicity score for pathogenic variants (Figure S3 and Table
S5). Autosomal-recessive NSHL variants recategorized as
benign had a significantly lower pathogenicity score for
seven of the eight methods used including the composite
score and SVM score (p < 0.05). These data support the re-
categorization of these variants as benign and the MAF
threshold we propose.2, 2014
Figure 2. Distribution of Pathogenic Variants by Maximum
Minor Allele Frequency in 12 Populations
Autosomal-recessive (A) and autosomal-dominant (B) variants.
Dashed red line indicates MAF cut-offs for each inheritance
mode. Asterisk (*) indicates that the count extends beyond the
axis.Of the 177 dominant pathogenic deafness variants,
77 were present in controls. To establish a threshold for
autosomal-dominant NSHL, we used a hypothesis-based
method because no single mutation comprises the major-
ity of autosomal-dominant NSHL in any given population.
We assumed Hardy-Weinberg equilibrium as well as the
following generally accepted values: 1 in 500 prevalence
of NSHL, 80% genetic, 70% nonsyndromic, 20% domi-
nant, and 56 dominant loci. These assumptions predict
that if there is only a single pathogenic variant in a given
autosomal-dominant NSHL gene, its MAF can be no higher
than 1/2,000 or 0.0005. We then used this threshold toThe Americrecategorize 20 variants as benign (Table S4). Pathogenicity
prediction scores were lower for 7 of 8 methods, and signif-
icantly lower for 4 of 8 methods including the composite
score and SVM score, again supporting this recategoriza-
tion of the variants (Figure S3 and Table S5).
Of the 93 variants we reclassified as benign, HGMD
contained calls for all but four (89) and classified 100%
of these as pathogenic or probable-pathogenic (Table S4
and Figure S4). In comparison, ClinVar and dbSNP con-
tained 41 of these variants but classified only 19 (46%) as
pathogenic. Our data indicate that although the HGMD
database contains more variants, it is not editable by users
and therefore may contain more false positives.
The importance of filtering against a large and diverse
control population is illustrated by our ability to recatego-
rize variants based on the populations used. Every popula-
tion used in this study, regardless of size, contained variants
above the MAF thresholds and therefore contributed to re-
categorization of variants (Figure 3). The contribution of
each population to recategorization of variants varied
from 38 variants above MAF threshold for the EVS African
American population to 10 variants above MAF threshold
for the OtoDB Japanese population (Figure 3). In addition,
the number of unique variants above MAF varied from 0 to
5, with all populations but one (OtoDB_JP) contributing at
least one unique ethnicity-specific variant above the set
MAF threshold (Figure 3). The size of the control popula-
tion did not correlate with the number of variants above
MAF threshold (r2 ¼ 0.15).
Of the 93 recategorized variants in this study, only 26%
would have been found to be above the proposed thresh-
olds when using a single population database—EVS Euro-
pean Americans, which contains 4,300 individuals, the
highest number of any database used in this study. How-
ever, by including other individuals of European descent
sequenced with the other two orthogonal platforms
(1000G EUR and OtoDB ES and US), 44% of the variants
rose above the cut-offs, reflecting differences in coverage
metrics and platform-specific weaknesses. As we added in-
dividuals from other ethnicities, we further improved our
ability to detect and therefore recategorize variants from
52% (after addition of Turkish and Ashkenazi Jewish
OtoDB individuals) to 64% after addition of Asian individ-
uals (1000G ASN and OtoDB JP) to 73% after addition of
American individuals (1000G AMR and OtoDB CO) and
finally to 100% after addition of African individuals (EVS
AA, 1000G AFR). These data support the need to generate
multiple ethnically discrete population databases on a va-
riety of different platforms and indicate that it may be
more important to have a large number of populations
from disparate ethnicities sequenced with orthogonal plat-
forms rather than a few populations of enormous size.
Interpretation of genetic variants is of primary concern
for clinical diagnosis and human genetics research, and
the MAF thresholds we propose—0.005 and 0.0005 MAF
for autosomal-recessive and autosomal-dominant NSHL
variants, respectively—provide thresholds for interpretingan Journal of Human Genetics 95, 445–453, October 2, 2014 451
Figure 3. Contribution of Each Population to Recategorization of 93 Previously Reported Pathogenic Variants
The count for each population is the number of variants found in each population above MAF threshold. Values for total, recessive, and
dominant variants are shown along with the number of variants above the MAF unique to that single population (Unique). Number of
individuals per population are listed in parenthesis on the x axis, also see Table 1.newly identified variants. Although these thresholds are
conservative, in clinical testing each variant should be in-
terpreted in the context of the phenotype and family his-
tory and with knowledge of the contribution of specific
deafness-causing variants to disease in the particular popu-
lation being studied.
Our study confirms the findings recently disqualifying
variants in MYO1A as a cause of deafness,9 as four of the
seven variants (57%) in MYO1A exceeded the MAF cut-
off we propose for autosomal-dominant NSHL and two
more fall immediately below this cut-off. MYO1A had
more variants recategorized as benign than any other
gene with variants reported to cause NSHL (Table 3). Our
data also suggest that particular attention should be paid
to two other genes with variants reported to cause NSHL
that we believe are questionable, namely GJB320 and
SLC26A5.21 These genes should be evaluated further to
determine whether variants in these genes truly cause fully
penetrant deafness.
This study has two important limitations. First, CNVs
were not included, and as we recently showed, their contri-
bution to NSHL is significant.22 A better understanding of
the pathogenicity of CNVs is needed. However, a large
number of controls must be analyzed using a reliable and
sensitive method to detect CNVs before this question can
be answered. Second, we did not ascertain all possible
pathogenic NSHL-causing variants. Although we did
attempt to collate a comprehensive list of reported patho-
genic deafness variants, invariably some variants have
been missed. For example, in the case of the Leiden-
Open Variant Database (LOVD), we could not reliably
retrieve variants in bulk from this database. This limitation
underscores the importance of standardizing the recording
of genetic data and making it freely accessible to improve
clinical care and research.
Ideally, each variant identified by genetic testing should
be evaluated in the context of the ethnic-specific preva-
lence of NSHL in the derivative population and also the
variant-specific MAF in a large number of ethnically
diverse populations. This study represents an important452 The American Journal of Human Genetics 95, 445–453, Octoberstep toward this goal but it is beyond the scope of this pa-
per to provide prevalence data for NSHL in the different
populations we studied. Although 1,872 variants (85.2%)
were not identified in the populations we studied, support-
ing their role in human deafness, we cannot unequivocally
ensure their pathogenicity as they could be present at high
MAF in populations we have not queried.
In conclusion, our results validate the use of multiple
platforms andmultiple ethnicities in filtering and ascribing
significance to genetic variants associated with NSHL. We
recategorized 93 previously reported pathogenic deafness
variants as benign. The MAF thresholds we propose will
facilitate the interpretation of newly discovered variants
in the context of NSHL. To further this goal, all data pre-
sented here are provided in the Deafness Variation Data-
base (see Web Resources), a freely available and regularly
updated database of all variants in known deafness genes.Supplemental Data
Supplemental Data include four figures and five tables and can be
found with this article online at http://dx.doi.org/10.1016/j.ajhg.
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